Novartis (Switzerland)

Browse company research profiles

Papers in the tracked journals with an author at Novartis (Switzerland): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education. Also as Markdown.

← Corporate research

Key findings#

From 2017 to 2026 (so far), authors at Novartis (Switzerland) took part in 57 papers in the tracked journals, most of them in health economics and policy (36), statistics (14) and AI (3).
It ranks #46 among the companies publishing in the tracked journals from 2023 to 2025.
8 of them were published in 2025, against 6 in 2017.
Since 2023, the institutions with the most of these papers were Charité – Universitätsmedizin Berlin (3), Novartis (India) (3) and Pfizer (United States) (3).
The journals publishing most of them were Patient (6), PharmacoEconomics (2) and The European Journal of Health Economics (2).
The most-cited of them is “Online payment fraud: from anomaly detection to risk management” (Financial Innovation, 2023), with 145 citations.
Since 2023, papers in the tracked journals cited 18 of its papers 66 times; 95% of those links came from papers with a university author and 2% from its own papers.
Its own papers since 2023 cite archived papers 29 times, 10% of them papers with a company author.
Across everything OpenAlex indexes, Novartis (Switzerland) has 22,324 works with 3,441,908 citations (h-index 635).
The tracked journals hold 56 of its 8,967 works in OpenAlex from 2017 to 2025 (0.6%).
Its main research topics in OpenAlex are Statistical Methods in Clinical Trials (1,129), Health Systems, Economic Evaluations, Quality of Life (964) and Computational Drug Discovery Methods (873).

Papers per year#

20172026 (so far)

Papers per publication year and category
Category	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026 (so far)
Health Economics and Policy	4	3	1	2	8	4	5	4	5	0
Statistics	2	1	1	0	5	1	1	1	1	1
AI	0	0	0	0	0	0	0	1	2	0
Finance	0	0	0	0	1	0	1	0	0	0
Marketing	0	0	0	1	0	0	0	0	0	0
Management	0	0	0	0	0	1	0	0	0	0
All categories	6	4	2	3	14	6	7	6	8	1

Where the papers come from#

Journals with the most papers, since 2023
#	Journal	Papers
1	Patient	6
2	PharmacoEconomics	2
3	The European Journal of Health Economics	2
4	Nature Machine Intelligence	2
5	Annals of the Institute of Statistical Mathematics	1
6	Health Policy	1
7	Journal of Statistical Planning and Inference	1
8	Artificial Intelligence in Medicine	1
9	BMC Medical Research Methodology	1
10	Cost Effectiveness and Resource Allocation	1

Institutions with the most papers, since 2023
#	Institution	Papers
1	Charité – Universitätsmedizin Berlin	3
2	Novartis (India)	3
3	Pfizer (United States)	3
4	AstraZeneca (Sweden)	2
5	Bayer (Germany)	2
6	Erasmus University Rotterdam	2
7	F. Hoffmann-La Roche AG	2
8	Janssen Research & Development (United States)	2
9	Medical University of Vienna	2

Countries with the most papers, since 2023
#	Country	Papers
1	Switzerland	22
2	United States	10
3	United Kingdom	9
4	Germany	7
5	Austria	3
6	Spain	3
7	India	3
8	Sweden	3
9	France	2
10	Ireland	2

Keywords with the most papers, since 2023
#	Keyword	Papers
1	cost-effectiveness	4
2	disease-modifying therapy	2
3	drug development	2
4	health technology assessment	2
5	methotrexate	2
6	mode of administration	2
7	patient experience	2
8	patient-reported outcomes	2
9	quality-adjusted life years	2
10	AI validation	1

Most-cited papers#

Most-cited papers since 2017
#	Citations	Per month	Title	Journal	Published	Authors
1	145	3.3	Online payment fraud: from anomaly detection to risk management	Financial Innovation	2023-03-12	Paolo Vanini, Sebastiano Rossi, Ermin Zvizdic et al.
2	102	1.7	Machine learning for financial forecasting, planning and analysis: recent developments and pitfalls	Digital Finance	2021-12-16	Helmut Wasserbacher, Martin Spindler
3	71	0.9	HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies	The European Journal of Health Economics	2020-08-13	Doug Coyle, Isabelle Durand‐Zaleski, Jasmine Farrington et al.
4	46	0.7	Mixture Cure Models in Oncology: A Tutorial and Practical Guidance	PharmacoEconomics - Open	2021-02-26	Federico Felizzi, Noman Paracha, Johannes Pöhlmann et al.
5	42	2.1	Data-driven federated learning in drug discovery with knowledge distillation	Nature Machine Intelligence	2025-03-05	Thierry Hanser, Ernst Ahlberg, Alexander Amberg et al.
6	32	0.8	Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical Recommendations	PharmacoEconomics	2023-07-25	Kumar Mukherjee, Necdet B. Gunsoy, Rita M. Kristy et al.
7	32	1.3	A call for an industry-led initiative to critically assess machine learning for real-world drug discovery	Nature Machine Intelligence	2024-10-04	Cas Wognum, Jeremy R. Ash, Matteo Aldeghi et al.
8	30	0.4	Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden	PharmacoEconomics	2021-01-25	R Mahon, Andrea Lang, Pamela G. Vo et al.
9	28	0.4	Do not miss the boat to outside-in open innovation: Enable your employees	Industrial Marketing Management	2020-09-11	Stefan Marković, Mehdi Bagherzadeh, Anna Dubiel et al.
10	24	0.2	Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK	PharmacoEconomics	2018-05-24	Paul Emery, Marjolijn van Keep, SM Beard et al.

Who cites its research#

Institutions whose papers cite it most, since 2023
#	Institution	Kind	Country	Links
1	Innsbruck Medical University	University	Austria	5
2	University of Manchester	University	United Kingdom	5
3	University of Sheffield	University	United Kingdom	5
4	Curtin University	University	Australia	4
5	The University of Sydney	University	Australia	3
6	Lundbeck (Denmark)	Company	Denmark	3
7	Universität Innsbruck	University	Austria	3
8	Ludwig-Maximilians-Universität München	University	Germany	3
9	Higher Colleges of Technology	University	United Arab Emirates	2
10	Ahvaz Jundishapur University of Medical Sciences	University	Iran	2

What its papers cite#

Institutions its papers cite most, since 2023
#	Institution	Kind	Country	Links
1	Erasmus University Rotterdam	University	Netherlands	4
2	Erasmus MC	Healthcare	Netherlands	3
3	University of Manchester	University	United Kingdom	3
4	University of York	University	United Kingdom	3
5	North Carolina State University	University	United States	2
6	University of Basel	University	Switzerland	2
7	Universitätsmedizin Greifswald	Healthcare	Germany	2
8	Universität Greifswald	University	Germany	2
9	London School of Hygiene & Tropical Medicine	University	United Kingdom	2
10	Amsterdam University Medical Centers	Healthcare	Netherlands	2

Citation links inside the tracked journals; see the corporate citation network and industry–university links.

In OpenAlex#

Novartis (Switzerland) in OpenAlex
Item	Value
Type	Company
Location	Basel, Basel-City, Switzerland
Units listed in OpenAlex	28
Works in OpenAlex	22,324
Citations	3,441,908
h-index	635
i10-index	33,215
2-year mean citedness	8.20
Website	www.novartis.com
ROR	ror.org/02f9zrr09
OpenAlex	openalex.org/I1283582996

Main research topics (OpenAlex, all works)
#	Topic	Field	Works
1	Statistical Methods in Clinical Trials	Mathematics	1,129
2	Health Systems, Economic Evaluations, Quality of Life	Economics, Econometrics and Finance	964
3	Computational Drug Discovery Methods	Computer Science	873
4	Psoriasis: Treatment and Pathogenesis	Immunology and Microbiology	804
5	Asthma and respiratory diseases	Medicine	774

Works and citations per year in OpenAlex, and its papers in the tracked journals
Year	Works in OpenAlex	Citations received	In the tracked journals	Share
2026 (so far)	690	58,303	1	0.1%
2025	1,178	74,117	8	0.7%
2024	921	75,026	6	0.7%
2023	1,019	71,285	7	0.7%
2022	1,129	71,054	6	0.5%
2021	1,098	74,343	14	1.3%
2020	932	67,943	3	0.3%
2019	888	58,001	2	0.2%
2018	936	53,480	4	0.4%
2017	866	51,800	6	0.7%

From OpenAlex's own record of the institution (CC0), read again monthly. Works and citations count everything OpenAlex indexes, not only the tracked journals; topics are OpenAlex's classification of those works.

Cite this page

Scholar4AI. (2026). Novartis (Switzerland). Journal and Conference Research Rankings. Retrieved November 5, 2026, from https://scholar4ai.com/companies/novartis-switzerland

@misc{scholar4ai-companies-novartis-switzerland,
  author = {{Scholar4AI}},
  title = {Novartis (Switzerland)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/novartis-switzerland}},
  urldate = {2026-11-05},
  note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}

Free to reuse for non-commercial purposes with attribution (CC BY-NC 4.0).